November 14, 2017 – LAS VEGAS – Isodiol International Inc., a global Bioactive Phytoceutical company specializing in the development of pharmaceutical and nutraceutical products, announced today the U.S. sales launch of ImmunAG, a non-cannabis cannabidiol (CBD) product derived from the hops plant. The time-released tablet will be unveiled at the Marijuana Business Conference and Expo (MJBizCon) in Las Vegas and available for purchase through Isodiol’s website, according to a press release.
“The release of ImmunAG is a monumental milestone for Isodiol, as it marks the industry’s first foray into non-cannabis CBD products,” said Marcos Agramont, CEO of Isodiol. “This launch is a continuation of our company strategy to provide a diverse range of products as we strive to increase shareholder value by creating entirely new market segments.”
Using proprietary extraction and purification methodologies, Isodiol is able to maintain the bioactivity (or a substances’ effectiveness on a target) of the molecule at a level much greater than anything currently derived from the cannabis plant. The ImmunAG tablet does not dissolve in the stomach but rather dissolves in the lower intestine, creating greater bioactivity.
“Cannabis is accepted by less than 10% of the world, while the hops plant is accepted universally,” said Agramont. “This significant expansion of the global marketplace, paired with our ability to manufacture and distribute the product world-wide, gives us access to practically every country and avails this product and subsequent products to the global marketplace.”
The company will be exhibiting all its product offerings at Booth #714 and #4699 of MJBizCon from Nov. 15-17.
For more information on Isodiol, please visit www.isodiol.com.
